Home › Compare › HHOLF vs ABBV
HHOLF yields 4000.00% · ABBV yields 3.06%● Live data
📍 HHOLF pulled ahead of the other in Year 1
Combined, HHOLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HHOLF + ABBV for your $10,000?
Herald Holdings Limited, together with its subsidiaries, engages in the manufacture, sale, and distribution of toys, computer products, housewares, clocks, watches, and electronic and gift products. It offers a range of toys, including action figures, electronic radio-controlled toy cars and boats, electronic games, and pre-school toys; battery-operated and electronic toys, games, radio-controlled vehicles, transformers, and model kits and gift items. The company provides computer products, including magnetic tape head, thin-film tape heads, and motor actuator assemblies, as well as smart connected devices for Internet of Things comprising smart watches, thermostats, sensory array gateways, and remote environmental sensors; and manufactures and sells watches under the Braun, Vivienne Westwood, and Lambretta brands. In addition, it is involved in the property investment and leasing activities; provision of marketing services; and debt and equity securities, and managed funds investment activities, as well as sells and distributes clocks, watches, and electronic products. Herald Holdings Limited operates in Hong Kong, North America, the United Kingdom, rest of Europe, Asia, Mainland China, and internationally. The company was incorporated in 1992 and is headquartered in Hong Kong, Hong Kong.
Full HHOLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.